Dual roles of apolipoprotein CI in the Formation of atherogenic remnants Johan Björkegren Invited Commentary Pages: 1 - 2
Should all diabetic patients receive statins? Paul J. GarciaCraig W. Spellman OriginalPaper Pages: 13 - 18
Low-density lipoprotein reduction: Is the risk worth the benefit? Anup K. SabharwalJeffrey B. Boord OriginalPaper Pages: 19 - 25
Other than potency, are all statins the same? Nicola AbateManisha Chandalia OriginalPaper Pages: 26 - 31
Dyslipidemia in special populations: Asian Indians, African Americans, and Hispanics Vibhuti SinghPrakash Deedwania OriginalPaper Pages: 32 - 40
The effects of statins on high-density lipoproteins Ernst J. SchaeferBela F. Asztalos OriginalPaper Pages: 41 - 49
Oxidized low-density lipoprotein biomarkers in atherosclerosis Sotirios Tsimikas OriginalPaper Pages: 55 - 61
Serum amyloid A: The “other” inflammatory protein Kevin D. O’BrienAlan Chait OriginalPaper Pages: 62 - 68
Effective use of combination lipid therapy Abu R. VasudevanPeter H. Jones OriginalPaper Pages: 76 - 84